Ben R. Taylor - 19 Dec 2024 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role: Chief Financial Officer
Signature: Jonathan D. Golightly, attorney-in-fact
Issuer symbol: RXRX
Transactions as of: 19 Dec 2024
Net transactions value: $0
Form type: 4
Filing time: 20 Dec 2024, 16:16:57 UTC
Previous filing: 18 Dec 2024
Next filing: 05 Feb 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RXRX	Class A Common Stock	Award	$0	+370,343	+78%	$0.000000	844,210	19 Dec 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RXRX	Stock Option (Right to Buy)	Award	$0	+740,686		$0.000000	740,686	19 Dec 2024	Class A Common Stock	740,686	$6.09	Direct	F2
holding	RXRX	Stock Option (Right to Buy)						289,837	19 Dec 2024	Class A Common Stock	0	$0.0400	Direct	F3
holding	RXRX	Stock Option (Right to Buy)						92,748	19 Dec 2024	Class A Common Stock	0	$0.0600	Direct	F4
holding	RXRX	Stock Option (Right to Buy)						81,154	19 Dec 2024	Class A Common Stock	0	$0.1400	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent an award of restricted stock units which vest as to 1/16th of the shares subject to the award quarterly, beginning February 15, 2025, subject to the Mr. Taylor's continued service through each vesting date.
F2	1/48th of the shares subject to the award vests and become exercisable on January 2, 2025, and each month thereafter, subject to Mr. Taylor's continued service through each vesting date.
F3	Twenty-five percent of the shares subject to the award vest and become exercisable on November 17, 2021, and the remaining shares subject to the award vest and become exercisable in annual installments thereafter, subject to Mr. Taylor's continued service through each vesting date.
F4	Twenty-five percent of the shares subject to the award vest and become exercisable on April 3, 2022, and the remaining shares subject to the award vest and become exercisable in quarterly installments thereafter, subject to Mr. Taylor's continued service through each vesting date.
F5	Twenty-five percent of the shares subject to the award vest and become exercisable on July 1, 2022, and the remaining shares subject to the award vest and become exercisable in quarterly installments thereafter, subject to Mr. Taylor's continued service through each vesting date.